Skip to main content
Erschienen in: Strahlentherapie und Onkologie 12/2016

24.10.2016 | Review Article

Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer

Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy

verfasst von: Dr.med. Cédric Panje, PD Dr. med. Nikolaus Andratschke, Prof. Dr. med. Thomas B. Brunner, PD Dr. med. Maximilian Niyazi, Prof. Dr. med. Matthias Guckenberger

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This report of the Working Group on Stereotactic Radiotherapy of the German Society of Radiation Oncology (DEGRO) aims to provide a literature review and practice recommendations for stereotactic body radiotherapy (SBRT) of primary renal cell cancer and primary pancreatic cancer.

Methods

A literature search on SBRT for both renal cancer and pancreatic cancer was performed with focus on prospective trials and technical aspects for clinical implementation.

Results

Data on renal and pancreatic SBRT are limited, but show promising rates of local control for both treatment sites. For pancreatic cancer, fractionated SBRT should be preferred to single-dose treatment to reduce the risk of gastrointestinal toxicity. Motion-compensation strategies and image guidance are paramount for safe SBRT delivery in both tumor entities.

Conclusion

SBRT for renal cancer and pancreatic cancer have been successfully evaluated in phase I and phase II trials. Pancreatic SBRT should be practiced carefully and only within prospective protocols due to the risk of severe gastrointestinal toxicity. SBRT for primary renal cell cancer appears a viable option for medically inoperable patients but future research needs to better define patient selection criteria and the detailed practice of SBRT.
Literatur
2.
Zurück zum Zitat Guckenberger M, Andratschke N, Alheit H et al (2014) Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol 190:26–33. doi:10.1007/s00066-013-0450-y CrossRefPubMed Guckenberger M, Andratschke N, Alheit H et al (2014) Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol 190:26–33. doi:10.​1007/​s00066-013-0450-y CrossRefPubMed
3.
Zurück zum Zitat Sterzing F, Brunner TB, Ernst I et al (2014) Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 190:872–881. doi:10.1007/s00066-014-0714-1 CrossRefPubMed Sterzing F, Brunner TB, Ernst I et al (2014) Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 190:872–881. doi:10.​1007/​s00066-014-0714-1 CrossRefPubMed
7.
10.
Zurück zum Zitat Stein M, Kuten A, Halpern J et al (1992) The value of postoperative irradiation in renal cell cancer. Radiother Oncol 24:41–44CrossRefPubMed Stein M, Kuten A, Halpern J et al (1992) The value of postoperative irradiation in renal cell cancer. Radiother Oncol 24:41–44CrossRefPubMed
12.
13.
Zurück zum Zitat Wilson D, Hiller L, Gray L et al (2003) The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 15:400–407CrossRef Wilson D, Hiller L, Gray L et al (2003) The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 15:400–407CrossRef
15.
20.
Zurück zum Zitat Pham D, Thompson A, Kron T et al (2014) Stereotactic ablative body radiation therapy for primary kidney cancer: a 3‑dimensional conformal technique associated with low rates of early toxicity. Int J Radiat Oncol Biol Phys 90:1061–1068. doi:10.1016/j.ijrobp.2014.07.043 CrossRefPubMed Pham D, Thompson A, Kron T et al (2014) Stereotactic ablative body radiation therapy for primary kidney cancer: a 3‑dimensional conformal technique associated with low rates of early toxicity. Int J Radiat Oncol Biol Phys 90:1061–1068. doi:10.​1016/​j.​ijrobp.​2014.​07.​043 CrossRefPubMed
23.
24.
Zurück zum Zitat Beitler JJ, Makara D, Silverman P, Lederman G (2004) Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am J Clin Oncol 27:646–648CrossRefPubMed Beitler JJ, Makara D, Silverman P, Lederman G (2004) Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am J Clin Oncol 27:646–648CrossRefPubMed
27.
30.
Zurück zum Zitat Siva S, Ellis RJ, Ponsky L et al (2016) Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncol 12:637–645. doi:10.2217/fon.16.2 CrossRefPubMed Siva S, Ellis RJ, Ponsky L et al (2016) Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncol 12:637–645. doi:10.​2217/​fon.​16.​2 CrossRefPubMed
33.
34.
Zurück zum Zitat Valakh V, Chan P, D’Adamo K, Micaily B (2013) Early-stage central lung cancer and volumetric modulated arc therapy: a dosimetric case study with literature review. Anticancer Res 33:4491–4495PubMed Valakh V, Chan P, D’Adamo K, Micaily B (2013) Early-stage central lung cancer and volumetric modulated arc therapy: a dosimetric case study with literature review. Anticancer Res 33:4491–4495PubMed
35.
Zurück zum Zitat Ning S, Trisler K, Wessels BW, Knox SJ (1997) Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80:2519–2528CrossRefPubMed Ning S, Trisler K, Wessels BW, Knox SJ (1997) Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80:2519–2528CrossRefPubMed
44.
Zurück zum Zitat Huguet F, André T, Hammel P et al (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25:326–331. doi:10.1200/JCO.2006.07.5663 CrossRefPubMed Huguet F, André T, Hammel P et al (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25:326–331. doi:10.​1200/​JCO.​2006.​07.​5663 CrossRefPubMed
47.
Zurück zum Zitat Hammel P, Huguet F, van Laethem J‑L et al (2016) Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of Gemcitabine with or without Erlotinib: the LAP07 randomized clinical trial. JAMA 315:1844–1853. doi:10.1001/jama.2016.4324 CrossRefPubMed Hammel P, Huguet F, van Laethem J‑L et al (2016) Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of Gemcitabine with or without Erlotinib: the LAP07 randomized clinical trial. JAMA 315:1844–1853. doi:10.​1001/​jama.​2016.​4324 CrossRefPubMed
51.
Zurück zum Zitat Koong AC, Christofferson E, Le Q‑T et al (2005) Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63:320–323. doi:10.1016/j.ijrobp.2005.07.002 CrossRefPubMed Koong AC, Christofferson E, Le Q‑T et al (2005) Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63:320–323. doi:10.​1016/​j.​ijrobp.​2005.​07.​002 CrossRefPubMed
53.
Zurück zum Zitat Schellenberg D, Kim J, Christman-Skieller C et al (2011) Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 81:181–188. doi:10.1016/j.ijrobp.2010.05.006 CrossRefPubMed Schellenberg D, Kim J, Christman-Skieller C et al (2011) Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 81:181–188. doi:10.​1016/​j.​ijrobp.​2010.​05.​006 CrossRefPubMed
55.
Zurück zum Zitat Herman JM, Chang DT, Goodman KA et al (2015) Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 121:1128–1137. doi:10.1002/cncr.29161 CrossRefPubMed Herman JM, Chang DT, Goodman KA et al (2015) Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 121:1128–1137. doi:10.​1002/​cncr.​29161 CrossRefPubMed
56.
Zurück zum Zitat Comito T, Cozzi L, Clerici E et al (2016) Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study. Technol Cancer Res Treat. doi:10.1177/1533034616650778 PubMed Comito T, Cozzi L, Clerici E et al (2016) Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study. Technol Cancer Res Treat. doi:10.​1177/​1533034616650778​ PubMed
62.
64.
65.
69.
72.
73.
Zurück zum Zitat Mellon EA, Hoffe SE, Springett GM et al (2015) Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol 54:979–985. doi:10.3109/0284186X.2015.1004367 CrossRefPubMed Mellon EA, Hoffe SE, Springett GM et al (2015) Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol 54:979–985. doi:10.​3109/​0284186X.​2015.​1004367 CrossRefPubMed
Metadaten
Titel
Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer
Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy
verfasst von
Dr.med. Cédric Panje
PD Dr. med. Nikolaus Andratschke
Prof. Dr. med. Thomas B. Brunner
PD Dr. med. Maximilian Niyazi
Prof. Dr. med. Matthias Guckenberger
Publikationsdatum
24.10.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 12/2016
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-016-1053-1

Weitere Artikel der Ausgabe 12/2016

Strahlentherapie und Onkologie 12/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.